文献速递慢阻肺肺栓塞与肺血管病

急性四氢生物蝶呤改善慢阻肺患者内皮功能

Acute Tetrahydrobiopterin Improves Endothelial Function in Patients With COPD.
PubMed 文献 · Chest · 2018-04-26

BH4可能成为改善慢阻肺患者内皮功能的新疗法。

要点

  • 单次BH4可显著改善慢阻肺患者内皮功能至接近对照组水平
  • BH4改善内皮功能伴随NOS3磷酸化比例增加
  • BH4可能降低慢阻肺患者心血管疾病风险

核心结论

  • 单次BH4可改善慢阻肺患者内皮功能至与对照组相似水平,并伴随NOS3磷酸化增加,可能成为改善内皮功能、降低心血管风险的新疗法。

关键数值与推荐

  • FMD在治疗前及治疗后3小时测量;内皮细胞与患者治疗前后血浆孵育后评估磷酸化及总NOS3蛋白。

临床怎么用

  • 提示BH4可能作为改善慢阻肺患者内皮功能、降低心血管风险的潜在新型治疗,但需进一步临床研究验证。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Cardiovascular diseases represent a hallmark characteristic in COPD, and endothelial dysfunction has been observed in these patients. Tetrahydrobiopterin (BH4) is an essential cofactor for nitric oxide (NO) synthesis and a regulator of endothelial function. The goal of this study was to test the hypothesis that a single dose of BH4 would improve endothelial function in patients with COPD via an increase in NO bioavailability. METHODS: Seventeen patients with COPD completed a randomized, double-blind, placebo (PLC)-controlled, crossover trial with an acute dose of either BH4 (Kuvan; BioMarin Pharmaceutical Inc) or PLC. Flow-mediated dilation (FMD), a bioassay of endothelial function, was completed prior to and 3 h following each treatment. Phospho- and total endothelial NO synthase (NOS3) protein was evaluated after incubating endothelial cells with plasma from the patients prior to and following treatment. Fifteen demographically matched control subjects were tested at baseline for case control comparisons. RESULTS: Treatment with BH4 significantly (P ≤ .004) increased FMD, improving endothelial function in patients compared to control values (P ≥ .327). BH4 increased (P = .013) the ratio of phospho-NOS3 to total NOS3 protein. No changes in FMD (P ≥ .776) or the protein ratio (P = .536) were observed following PLC. CONCLUSIONS: An acute dose of BH4 was able to improve endothelial function in patients with COPD to values similar to control subjects. The improvement in endothelial function was accompanied by an increase in NOS3 phosphorylation. BH4 may represent a potential novel therapy to improve endothelial function and reduce cardiovascular disease risk in patients with COPD. TRIAL REGISTRY: ClinicalTrials.gov; No.: NCT01398943; URL: www.clinicaltrials.gov.

来源:Chest,查看原文。版权归原作者所有。

引用

  1. Rodriguez-Miguelez P, Gregg J, Seigler N, et al. Acute Tetrahydrobiopterin Improves Endothelial Function in Patients With COPD. Chest. 2018. PMID: 29705218. doi:10.1016/j.chest.2018.04.028

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。